Tags

Type your tag names separated by a space and hit enter

Evaluation of a point-of-care test based on deamidated gliadin peptides for celiac disease screening in a large pediatric population.
Eur J Gastroenterol Hepatol. 2012 Dec; 24(12):1418-23.EJ

Abstract

OBJECTIVES

Celiac disease (CD) is nowadays known to be a common chronic enteropathy that is becoming a growing public health concern. Yet, it is estimated that more than 90% of patients remain undiagnosed. A point-of-care diagnostic test can be a rapid and cost-effective solution in the first-line screening of CD. The aim of this study is to evaluate the performance of a novel point-of-care screening test in a large pediatric population.

MATERIALS AND METHODS

Serum samples were collected from a cohort of 250 children presenting either an increased risk or a clinical suspicion of CD. All sera were tested using the point-of-care test detecting IgA and IgG antibodies against a combination of three different deamidated gliadin peptides as well as total IgA. The results of the screening test were compared with an enzyme-linked tissue transglutaminase immunosorbent assay and with histology resulting from intestinal biopsies performed in patients with elevated titers of antitissue transglutaminase antibodies.

RESULTS

The point-of-care test showed highly concordant results with the laboratory immunoassay, yielding a sensitivity of 93.1 (78-98.1%) and a specificity of 95% (91.2-97.2%), with a diagnostic accuracy of 94.8% (91.3-96.9%) and a negative predictive value of 99.1% (96.6-99.7%). The screening test identified all patients with celiac-type histology findings on biopsy, as well as all patients with concomitant IgA deficiency.

CONCLUSION

With a high diagnostic accuracy, this novel point-of-care approach is an efficient tool for CD case finding in pediatric populations. It has the potential to improve the management of celiac patients in primary care by providing faster counseling and treatment.

Authors+Show Affiliations

Immunology Laboratory, Lyon-Sud University Hospital, Pierre-Bénite, France. francoise.bienvenu@chu-lyon.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23032795

Citation

Bienvenu, Françoise, et al. "Evaluation of a Point-of-care Test Based On Deamidated Gliadin Peptides for Celiac Disease Screening in a Large Pediatric Population." European Journal of Gastroenterology & Hepatology, vol. 24, no. 12, 2012, pp. 1418-23.
Bienvenu F, Besson Duvanel C, Seignovert C, et al. Evaluation of a point-of-care test based on deamidated gliadin peptides for celiac disease screening in a large pediatric population. Eur J Gastroenterol Hepatol. 2012;24(12):1418-23.
Bienvenu, F., Besson Duvanel, C., Seignovert, C., Rouzaire, P., Lachaux, A., & Bienvenu, J. (2012). Evaluation of a point-of-care test based on deamidated gliadin peptides for celiac disease screening in a large pediatric population. European Journal of Gastroenterology & Hepatology, 24(12), 1418-23. https://doi.org/10.1097/MEG.0b013e3283582d95
Bienvenu F, et al. Evaluation of a Point-of-care Test Based On Deamidated Gliadin Peptides for Celiac Disease Screening in a Large Pediatric Population. Eur J Gastroenterol Hepatol. 2012;24(12):1418-23. PubMed PMID: 23032795.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of a point-of-care test based on deamidated gliadin peptides for celiac disease screening in a large pediatric population. AU - Bienvenu,Françoise, AU - Besson Duvanel,Cécile, AU - Seignovert,Camille, AU - Rouzaire,Paul, AU - Lachaux,Alain, AU - Bienvenu,Jacques, PY - 2012/10/4/entrez PY - 2012/10/4/pubmed PY - 2013/4/9/medline SP - 1418 EP - 23 JF - European journal of gastroenterology & hepatology JO - Eur J Gastroenterol Hepatol VL - 24 IS - 12 N2 - OBJECTIVES: Celiac disease (CD) is nowadays known to be a common chronic enteropathy that is becoming a growing public health concern. Yet, it is estimated that more than 90% of patients remain undiagnosed. A point-of-care diagnostic test can be a rapid and cost-effective solution in the first-line screening of CD. The aim of this study is to evaluate the performance of a novel point-of-care screening test in a large pediatric population. MATERIALS AND METHODS: Serum samples were collected from a cohort of 250 children presenting either an increased risk or a clinical suspicion of CD. All sera were tested using the point-of-care test detecting IgA and IgG antibodies against a combination of three different deamidated gliadin peptides as well as total IgA. The results of the screening test were compared with an enzyme-linked tissue transglutaminase immunosorbent assay and with histology resulting from intestinal biopsies performed in patients with elevated titers of antitissue transglutaminase antibodies. RESULTS: The point-of-care test showed highly concordant results with the laboratory immunoassay, yielding a sensitivity of 93.1 (78-98.1%) and a specificity of 95% (91.2-97.2%), with a diagnostic accuracy of 94.8% (91.3-96.9%) and a negative predictive value of 99.1% (96.6-99.7%). The screening test identified all patients with celiac-type histology findings on biopsy, as well as all patients with concomitant IgA deficiency. CONCLUSION: With a high diagnostic accuracy, this novel point-of-care approach is an efficient tool for CD case finding in pediatric populations. It has the potential to improve the management of celiac patients in primary care by providing faster counseling and treatment. SN - 1473-5687 UR - https://www.unboundmedicine.com/medline/citation/23032795/Evaluation_of_a_point_of_care_test_based_on_deamidated_gliadin_peptides_for_celiac_disease_screening_in_a_large_pediatric_population_ L2 - https://doi.org/10.1097/MEG.0b013e3283582d95 DB - PRIME DP - Unbound Medicine ER -